GLP-1 and peptide prices: the dollars-per-milligram index

Why dollars-per-mg (and why "$/month" misleads)

A "$1,000/month" headline tells you almost nothing without the dose. Wegovy’s 2.4 mg weekly maintenance is about 9.6 mg a month; Zepbound’s 15 mg weekly is about 60 mg a month. Same ballpark monthly price, 6× difference in milligrams. Normalizing to $/mg is the only apples-to-apples way to compare across molecules — though it is not a measure of clinical equivalence, since different peptides do different things at different doses. Use $/mg for cost transparency, not as medical guidance.

Method

• $/mg computation: every dollars-per-milligram figure on this page is computed, never typed. The formula is price ÷ (mg per dose × doses per period), using the dose inputs printed beside each row. Weekly injectables are counted at four doses a month; daily orals at thirty. Nothing on this page carries a $/mg we cannot reproduce from its own inputs.
• Sources: manufacturer list prices, published wholesale acquisition cost, manufacturer self-pay programs, and compounding/telehealth program rates — each linked on the row it supports.
• Research-market compounds: no figures are published. The prices that used to appear here were transcribed from third-party buying guides rather than measured by us, so they have been withdrawn. Ranges will appear only after a documented first-party survey that can state its method, its date and how many sellers it covered.
• Recency: the newest figure on this page is dated 2026-09-16, and every row carries its own date; some are older, and a wholesale price that has not changed since 2025 is dated 2025. Prices — especially compounded and telehealth — change frequently; treat them as a snapshot, not a quote.
• List price is not net price. These are what a cash payer faces, not what the health system pays. A 2025 cost-effectiveness analysis in JAMA Health Forum estimated the net annual price of tirzepatide at roughly $6,236 and semaglutide at roughly $8,412 after rebates (Hwang et al., 2025).
• Independence: Peptides.NYC has no affiliate relationship with any product or pharmacy listed and sells nothing.

Keep reading: browse the full Sourcing library, or start from our Fat Loss hub to see how this page fits the wider picture. For the two leading GLP-1 options head to head, see tirzepatide vs semaglutide. For what this costs in New York specifically, see peptide therapy cost in NYC.

For what this costs at a New York clinic specifically, see our NYC clinic price survey — method published, figures published when clinics give them to us.

What changed, and when

1. 2026-09-16

   The Ozempic wholesale-acquisition-cost row ($935.77/mo) was withdrawn. This page promises that every figure is traceable to a primary source, and that one is not: GoodRx returns the page but renders its prices in the browser, so the figure never appears in the document, and Novo Nordisk publishes no reachable pricing disclosure — every candidate URL returns 404. A number we cannot show you the source for does not belong on a price index, so it is gone rather than flagged. The Ozempic list price of $1,027.51 is unaffected and remains, confirmed against NovoCare. Tirzepatide’s wholesale acquisition cost also remains, since Lilly publishes it.

2. 2026-09-16

   Re-checked every manufacturer figure against its own source. The Wegovy self-pay row was withdrawn: Novo Nordisk lowered self-pay from $499 to $349 on 2025-11-17, and neither wegovy.com nor NovoCare shows a $499 Wegovy price today, so the row was a superseded number sitting beside the $349 that replaced it. Ozempic 2 mg self-pay ($499), Wegovy self-pay ($349), the Ozempic and Wegovy list prices, the Mounjaro wholesale acquisition cost, and the Zepbound and Rybelsus no-price findings were all re-read from the manufacturer today. Three rows could not be re-read at all — both Zepbound single-dose-vial rows and the oral Wegovy self-pay row, whose sources return HTTP 403 — and now say so instead of carrying the migration date. A fourth, the Ozempic wholesale acquisition cost, could not be sourced at all and was withdrawn; see above.

   Rows affected: ozempic-pen-list, ozempic-pen-self-pay, wegovy-list, wegovy-self-pay-pharmacy-direct, mounjaro-wac-pack, zepbound-pen-no-list-price, zepbound-vial-self-pay-7-5mg, zepbound-vial-self-pay-15mg, rybelsus-no-list-price, ozempic-tablets-list, oral-wegovy-self-pay

3. 2026-09-16

   Moved from the /learn article to /prices. Every dollars-per-milligram figure is now computed from the dose inputs shown beside it rather than typed by hand, so a figure can no longer drift from the label it sits next to. Dates now record when each figure is current, not when we copied it: the Mounjaro wholesale acquisition cost is stamped January 2025 and says so.

   Rows affected: ozempic-pen-list, ozempic-pen-self-pay, wegovy-list, wegovy-self-pay-pharmacy-direct, mounjaro-wac-pack, zepbound-pen-no-list-price, zepbound-vial-self-pay-7-5mg, zepbound-vial-self-pay-15mg, rybelsus-no-list-price, ozempic-tablets-list, oral-wegovy-self-pay, compounded-semaglutide-injectable-hims, compounded-semaglutide-oral-hims, compounded-semaglutide-injectable-ro, compounded-semaglutide-injectable-noom, compounded-semaglutide-mochi, compounded-semaglutide-henry, compounded-tirzepatide-market, compounded-tirzepatide-mochi, compounded-tirzepatide-henry, compounded-tirzepatide-shedrx, compounded-tirzepatide-found, compounded-tirzepatide-trimi, compounded-semaglutide-trimi, ro-body-membership-fee, noom-med-program-fee, net-price-tirzepatide, net-price-semaglutide

4. 2026-09-16

   Corrected a figure whose arithmetic did not follow from its own stated inputs. The Zepbound self-pay row printed $14.97/mg against "5 mg weekly, 20 mg/month", which computes to $19.95; the figure belongs to the 7.5 mg tier ($449 over 30 mg), and the row now carries those inputs. The same recomputation found two research-market ranges that were also wrong — BPC-157 printed as $4.50-19/mg against $38-95 per 5 mg vial, GHK-Cu as $0.59-3/mg against $30-95 per 50 mg vial — but those rows were withdrawn entirely rather than corrected; see below.

   Rows affected: zepbound-vial-self-pay-7-5mg

5. 2026-09-16

   Zepbound pens and Rybelsus now show no price at all. Lilly publishes no Zepbound list price, stating only that savings are capped at wholesale acquisition cost minus $499, and the NovoCare Rybelsus page returns a live page carrying zero dollar figures. Both rows record that finding instead of repeating a third-party number; the Mounjaro wholesale acquisition cost is the closest published tirzepatide benchmark.

   Rows affected: zepbound-pen-no-list-price, rybelsus-no-list-price

6. 2026-09-16

   The research-market table is withheld in full. Eleven of its seventeen rows named a vendor and linked straight to that vendor’s product page; the other six were market ranges lifted from third-party buying guides. Three compounds (CJC-1295 with DAC, a CJC-1295/ipamorelin blend, and ipamorelin) existed only as storefront rows and were deleted outright. The six guide ranges were not anything Peptides.NYC measured, so republishing them under our own name would have been a methodology we did not have. Nothing replaces them until a documented first-party survey runs and can state its method, date and sample size.